Status:
UNKNOWN
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Guangdong Provincial People's Hospital
Third Affiliated Hospital, Sun Yat-Sen University
Conditions:
Acute Graft-versus-host Disease
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant ac...
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for several hematological disorders. Although good progress has been made in the prevention and treatment of side...
Eligibility Criteria
Inclusion
- age of 14-65 years
- steroid-resistant aGVHD
- subjects (or their legally acceptable representatives) must have signed an informed consent document
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02241018
Start Date
September 1 2014
End Date
December 1 2018
Last Update
September 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515